How Bacterial Pathogens Eat Host Lipids: Implications for the Development of Fatty Acid Synthesis Therapeutics*

Bacterial type II fatty acid synthesis (FASII) is a target for the development of novel therapeutics. Bacteria incorporate extracellular fatty acids into membrane lipids, raising the question of whether pathogens use host fatty acids to bypass FASII and defeat FASII therapeutics. Some pathogens suppress FASII when exogenous fatty acids are present to bypass FASII therapeutics. FASII inhibition cannot be bypassed in many bacteria because essential fatty acids cannot be obtained from the host. FASII antibiotics may not be effective against all bacteria, but a broad spectrum of Gram-negative and -positive pathogens can be effectively treated with FASII inhibitors.

[1]  Cecilia Jernberg,et al.  Long-term impacts of antibiotic exposure on the human intestinal microbiota. , 2010, Microbiology.

[2]  J. W. Campbell,et al.  Expression of Vibrio harveyi acyl-ACP synthetase allows efficient entry of exogenous fatty acids into the Escherichia coli fatty acid and lipid A synthetic pathways. , 2010, Biochemistry.

[3]  P. Mazzei,et al.  Cerinolactone, a hydroxy-lactone derivative from Trichoderma cerinum. , 2012, Journal of natural products.

[4]  T. Tompkins,et al.  Probiotics Reduce Enterohemorrhagic Escherichia coli O157:H7- and Enteropathogenic E. coli O127:H6-Induced Changes in Polarized T84 Epithelial Cell Monolayers by Reducing Bacterial Adhesion and Cytoskeletal Rearrangements , 2005, Infection and Immunity.

[5]  C. Rock,et al.  Membrane lipid homeostasis in bacteria , 2008, Nature Reviews Microbiology.

[6]  C. Rock,et al.  Isolation and characterization of Escherichia coli K-12 mutants lacking both 2-acyl-glycerophosphoethanolamine acyltransferase and acyl-acyl carrier protein synthetase activity. , 1991, The Journal of biological chemistry.

[7]  C. Rock,et al.  2-Acylglycerolphosphoethanolamine acyltransferase/acyl-acyl carrier protein synthetase is a membrane-associated acyl carrier protein binding protein. , 1989, The Journal of biological chemistry.

[8]  B. Staels,et al.  Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens , 2009, Nature.

[9]  C. Rock,et al.  Staphylococcus aureus Fatty Acid Auxotrophs Do Not Proliferate in Mice , 2013, Antimicrobial Agents and Chemotherapy.

[10]  R. W. Davis,et al.  Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. , 1998, Science.

[11]  K. Lewis Platforms for antibiotic discovery , 2013, Nature Reviews Drug Discovery.

[12]  M. Blaser,et al.  Antibiotics in early life alter the murine colonic microbiome and adiposity , 2012, Nature.

[13]  C. Raetz Enzymology, genetics, and regulation of membrane phospholipid synthesis in Escherichia coli. , 1978, Microbiological reviews.

[14]  C. Rock,et al.  Type II Fatty Acid Synthesis Is Essential for the Replication of Chlamydia trachomatis* , 2014, The Journal of Biological Chemistry.

[15]  D. Byers,et al.  Elongation of exogenous fatty acids by the bioluminescent bacterium Vibrio harveyi , 1989, Journal of bacteriology.

[16]  C. Rock,et al.  Forty years of bacterial fatty acid synthesis. , 2002, Biochemical and biophysical research communications.

[17]  N. Kaplan,et al.  AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  N. Salzman,et al.  Prolonged Impact of Antibiotics on Intestinal Microbial Ecology and Susceptibility to Enteric Salmonella Infection , 2009, Infection and Immunity.

[19]  L. Earls,et al.  Activation of hemolysin toxin: relationship between two internal protein sites of acylation. , 2004, Biochemistry.

[20]  S. Subrahmanyam,et al.  FadR, transcriptional co‐ordination of metabolic expediency , 1998, Molecular microbiology.

[21]  T. Kaneda,et al.  Iso- and anteiso-fatty acids in bacteria: biosynthesis, function, and taxonomic significance. , 1991, Microbiological reviews.

[22]  J. Coleman Characterization of the Escherichia coli gene for 1-acyl-sn-glycerol-3-phosphate acyltransferase (pIsC) , 1992, Molecular and General Genetics MGG.

[23]  Y. Becker The chlamydia: molecular biology of procaryotic obligate parasites of eucaryocytes , 1978, Microbiological reviews.

[24]  Diego de Mendoza,et al.  FapR, a bacterial transcription factor involved in global regulation of membrane lipid biosynthesis. , 2003, Developmental cell.

[25]  H. Nikaido Biosynthesis of cell wall lipopolysaccharide in gram-negative enteric bacteria. , 1968, Advances in enzymology and related areas of molecular biology.

[26]  C. Rock,et al.  Perturbation of Staphylococcus aureus Gene Expression by the Enoyl-Acyl Carrier Protein Reductase Inhibitor AFN-1252 , 2013, Antimicrobial Agents and Chemotherapy.

[27]  C. Rock,et al.  Preparative enzymatic synthesis and hydrophobic chromatography of acyl-acyl carrier protein. , 1979, The Journal of biological chemistry.

[28]  J. Cronan Expression of the biotin biosynthetic operon of Escherichia coli is regulated by the rate of protein biotination. , 1988, The Journal of biological chemistry.

[29]  N. Desroy,et al.  From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria. , 2012, Journal of medicinal chemistry.

[30]  Vladimir Romanov,et al.  Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor , 2012, Antimicrobial Agents and Chemotherapy.

[31]  C. Rock,et al.  Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery? , 2011, Current opinion in microbiology.

[32]  C. Raetz,et al.  Synthesis of a carbohydrate-derived hydroxamic acid inhibitor of the bacterial enzyme (LpxC) involved in lipid A biosynthesis. , 2003, Organic letters.

[33]  S. Salminen,et al.  Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus , 2007, Letters in applied microbiology.

[34]  Margret I. Moré,et al.  Enzymatic Synthesis of a Quorum-Sensing Autoinducer Through Use of Defined Substrates , 1996, Science.

[35]  E. Toone,et al.  Lipooligosaccharide is required for the generation of infectious elementary bodies in Chlamydia trachomatis , 2011, Proceedings of the National Academy of Sciences.

[36]  J. Cronan,et al.  The soluble acyl-acyl carrier protein synthetase of Vibrio harveyi B392 is a member of the medium chain acyl-CoA synthetase family. , 2006, Biochemistry.

[37]  P. Black,et al.  Cloning, sequencing, and expression of the fadD gene of Escherichia coli encoding acyl coenzyme A synthetase. , 1992, The Journal of biological chemistry.

[38]  A. Singh,et al.  Insertional Inactivation of Branched-Chain α-Keto Acid Dehydrogenase in Staphylococcus aureus Leads to Decreased Branched-Chain Membrane Fatty Acid Content and Increased Susceptibility to Certain Stresses , 2008, Applied and Environmental Microbiology.

[39]  C. Rock,et al.  Resistance to AFN-1252 Arises from Missense Mutations in Staphylococcus aureus Enoyl-acyl Carrier Protein Reductase (FabI)* , 2013, The Journal of Biological Chemistry.

[40]  F. Götz,et al.  Structure and Biosynthesis of Staphyloxanthin from Staphylococcus aureus* , 2005, Journal of Biological Chemistry.

[41]  J. Cronan,et al.  Inhibition of Escherichia coliAcetyl Coenzyme A Carboxylase by Acyl-Acyl Carrier Protein , 2001, Journal of bacteriology.

[42]  A. Merrill,et al.  Membrane phospholipid synthesis in Escherichia coli. Purification, reconstitution, and characterization of sn-glycerol-3-phosphate acyltransferase. , 1981, The Journal of biological chemistry.

[43]  J. Wylie,et al.  Host cell phospholipids are trafficked to and then modified by Chlamydia trachomatis , 1997, Journal of bacteriology.

[44]  I. Morrissey,et al.  The MUT056399 Inhibitor of FabI Is a New Antistaphylococcal Compound , 2011, Antimicrobial Agents and Chemotherapy.

[45]  R. P. Ross,et al.  Modification of the Technical Properties of Lactobacillus johnsonii NCC 533 by Supplementing the Growth Medium with Unsaturated Fatty Acids , 2011, Applied and Environmental Microbiology.

[46]  Laura J V Piddock,et al.  The crisis of no new antibiotics--what is the way forward? , 2012, The Lancet. Infectious diseases.

[47]  C. Rock,et al.  Incorporation of extracellular fatty acids by a fatty acid kinase‐dependent pathway in Staphylococcus aureus , 2014, Molecular microbiology.

[48]  S. Wakil,et al.  Control of Fatty Acid Metabolism I. Induction of the Enzymes of Fatty Acid Oxidation in Escherichia coli , 1969, Journal of bacteriology.

[49]  R J Heath,et al.  Mechanism of Triclosan Inhibition of Bacterial Fatty Acid Synthesis* , 1999, The Journal of Biological Chemistry.

[50]  C. Rock,et al.  Acyl-phosphates initiate membrane phospholipid synthesis in Gram-positive pathogens. , 2006, Molecular cell.

[51]  C. Rock,et al.  Sequence and function of the aas gene in Escherichia coli. , 1994, The Journal of biological chemistry.

[52]  M. Burkart,et al.  Versatility of acyl-acyl carrier protein synthetases. , 2014, Chemistry & biology.

[53]  Shutao Ma,et al.  Recent Advances in Inhibitors of Bacterial Fatty Acid Synthesis Type II (FASII) System Enzymes as Potential Antibacterial Agents , 2013, ChemMedChem.

[54]  Andrzej Witkowski,et al.  Structural and functional organization of the animal fatty acid synthase. , 2003, Progress in lipid research.

[55]  J. Cronan,et al.  Activation of long chain fatty acids with acyl carrier protein: demonstration of a new enzyme, acyl-acyl carrier protein synthetase, in Escherichia coli. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Coleman Characterization of the Escherichia coli gene for 1-acyl-sn-glycerol-3-phosphate acyltransferase (plsC). , 1992, Molecular & general genetics : MGG.

[57]  C. Rock,et al.  Transcriptional regulation of fatty acid biosynthesis in Streptococcus pneumoniae , 2006, Molecular microbiology.

[58]  T. Lampe,et al.  Novel Bacterial Acetyl Coenzyme A Carboxylase Inhibitors with Antibiotic Efficacy In Vivo , 2006, Antimicrobial Agents and Chemotherapy.

[59]  Z. Shen,et al.  Purification and characterization of fatty acyl-acyl carrier protein synthetase from Vibrio harveyi , 1993, Journal of bacteriology.

[60]  N. Kaplan,et al.  Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model , 2013, Journal of chemotherapy.

[61]  C. Rock,et al.  Bacterial lipids: metabolism and membrane homeostasis. , 2013, Progress in lipid research.

[62]  Chitra Subramanian,et al.  Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors , 2011, Proceedings of the National Academy of Sciences.

[63]  B. Berger,et al.  Identification of Genes Associated with the Long-Gut-Persistence Phenotype of the Probiotic Lactobacillus johnsonii Strain NCC533 Using a Combination of Genomics and Transcriptome Analysis , 2008, Journal of bacteriology.

[64]  C. Rock,et al.  Biosynthesis of Membrane Lipids , 2008, EcoSal Plus.

[65]  E. Snell,et al.  Oleic acid and related compounds as growth factors for lactic acid bacteria. , 1947 .

[66]  T. Silhavy,et al.  Lipoic Acid Metabolism in Escherichia coli : Isolation of Null Mutants Defective in Lipoic Acid Biosynthesis , Molecular Cloning and Characterization of the E . coli lip Locus , and Identification of the Lipoylated Protein of the Glycine Cleavage System , 2005 .

[67]  M. Débarbouillé,et al.  Structural Basis for Feed-Forward Transcriptional Regulation of Membrane Lipid Homeostasis in Staphylococcus aureus , 2013, PLoS pathogens.

[68]  N. Kaplan,et al.  In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics , 2013, Journal of chemotherapy.

[69]  C. Sotriffer,et al.  Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase Inhibitor* , 2014, The Journal of Biological Chemistry.

[70]  C. Rock,et al.  Phosphatidic acid synthesis in bacteria. , 2013, Biochimica et biophysica acta.

[71]  P. Overath,et al.  The induction of the enzymes of fatty acid degradation in Escherichia coli. , 1967, Biochemical and biophysical research communications.

[72]  S. Levy,et al.  Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.

[73]  R J Heath,et al.  Lipid biosynthesis as a target for antibacterial agents. , 2001, Progress in lipid research.

[74]  J. Davies,et al.  Origins and Evolution of Antibiotic Resistance , 1996, Microbiology and Molecular Biology Reviews.

[75]  K. Reynolds,et al.  Antibacterial targets in fatty acid biosynthesis. , 2007, Current opinion in microbiology.

[76]  C. Rock,et al.  Identification of a two-component fatty acid kinase responsible for host fatty acid incorporation by Staphylococcus aureus , 2014, Proceedings of the National Academy of Sciences.

[77]  C. Rock,et al.  Acyl-Acyl Carrier Protein Regulates Transcription of Fatty Acid Biosynthetic Genes via the FabT Repressor in Streptococcus pneumoniae* , 2009, The Journal of Biological Chemistry.